WO2009001673A1 - Ａｔｐ含有免疫アジュバント - Google Patents

Ａｔｐ含有免疫アジュバント Download PDF

Info

Publication number
WO2009001673A1
WO2009001673A1 PCT/JP2008/060641 JP2008060641W WO2009001673A1 WO 2009001673 A1 WO2009001673 A1 WO 2009001673A1 JP 2008060641 W JP2008060641 W JP 2008060641W WO 2009001673 A1 WO2009001673 A1 WO 2009001673A1
Authority
WO
WIPO (PCT)
Prior art keywords
immunoadjuvant
atp
vaccine composition
disclosed
solvate
Prior art date
Application number
PCT/JP2008/060641
Other languages
English (en)
French (fr)
Inventor
Shuji Sato
Takeshi Goto
Naoya Ohmori
Kueichen Chiang
Yayoi Shimada
Original Assignee
Josai University Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Josai University Corporation filed Critical Josai University Corporation
Priority to JP2009520440A priority Critical patent/JPWO2009001673A1/ja
Publication of WO2009001673A1 publication Critical patent/WO2009001673A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　本発明は、優れた抗体産生増強機能を有しかつ安全性の高い、免疫アジュバントおよびこれを含むワクチン組成物に関する。より詳しくは、本発明は、ＡＴＰ、またはその薬学上許容可能な塩、溶媒和物、もしくは生理学的機能を有するその誘導体を有効成分として含んでなる免疫アジュバントおよびそのワクチン組成物に関する。
PCT/JP2008/060641 2007-06-26 2008-06-11 Ａｔｐ含有免疫アジュバント WO2009001673A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009520440A JPWO2009001673A1 (ja) 2007-06-26 2008-06-11 Ａｔｐ含有免疫アジュバント

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92940407P 2007-06-26 2007-06-26
US60/929,404 2007-06-26

Publications (1)

Publication Number Publication Date
WO2009001673A1 true WO2009001673A1 (ja) 2008-12-31

Family

ID=40185494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060641 WO2009001673A1 (ja) 2007-06-26 2008-06-11 Ａｔｐ含有免疫アジュバント

Country Status (3)

Country Link
US (2) US20090081247A1 (ja)
JP (1) JPWO2009001673A1 (ja)
WO (1) WO2009001673A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012023614A1 (ja) * 2010-08-20 2012-02-23 学校法人 城西大学 免疫抑制活性を有するモノクローナル抗体またはその抗原結合断片
CN110680918A (zh) * 2019-10-10 2020-01-14 中国医学科学院医学生物学研究所 一种以atp为佐剂的hpv纳米疫苗组合物及其制备方法
WO2020227159A3 (en) * 2019-05-03 2020-12-10 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses
WO2006025580A1 (ja) * 2004-09-03 2006-03-09 Amateraspharma Inc. 抗ヒストンｈ１モノクローナル抗体およびこれを産生するハイブリドーマ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040137004A1 (en) * 2002-03-19 2004-07-15 Glenn Gregory M Patch for transcutaneous immunization

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses
WO2006025580A1 (ja) * 2004-09-03 2006-03-09 Amateraspharma Inc. 抗ヒストンｈ１モノクローナル抗体およびこれを産生するハイブリドーマ

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRANSTEIN R.D. ET AL.: "Augmentation of cutaneous immune responses by ATPgammaS: Purinergic agonists define a novel class of immunologic adjuvants", THE JOURNAL OF IMMUNOLOGY, vol. 174, 2005, pages 7725 - 7731 *
Men'ekigaku Yogo Jiten, Kabushiki Kaisha Saishin Igakusha, 30 November, 1984 (30.11.84), page 190 *
NAITO S.: "Keihi Men'eki Vaccine", CLINICAL IMMUNOLGY & ALLERGOLOGY, vol. 47, no. 2, 25 February 2007 (2007-02-25), pages 226 - 231 *
OMORI N. ET AL.: "Hifu Barrier Kino to Hifu o Kaisuru DDS no Shinpo Keihi Vaccine Delivery System", DRUG DELIVERY SYSTEM, vol. 22, no. 4, 30 July 2007 (2007-07-30), pages 468 - 475 *
SCHIJNS V.E.J.C.: "Immunological concepts of vaccine adjuvant activity", CURRENT OPINION IN IMMUNOLOGY, vol. 12, no. 4, August 2000 (2000-08-01), pages 456 - 463, XP004257704 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012023614A1 (ja) * 2010-08-20 2012-02-23 学校法人 城西大学 免疫抑制活性を有するモノクローナル抗体またはその抗原結合断片
JP5960596B2 (ja) * 2010-08-20 2016-08-02 学校法人 城西大学 免疫抑制活性を有するモノクローナル抗体またはその抗原結合断片
US9701739B2 (en) 2010-08-20 2017-07-11 Josai University Corporation Monoclonal antibody having immunosuppressive activity or antigen binding fragment thereof
WO2020227159A3 (en) * 2019-05-03 2020-12-10 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US11376272B2 (en) 2019-05-03 2022-07-05 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN110680918A (zh) * 2019-10-10 2020-01-14 中国医学科学院医学生物学研究所 一种以atp为佐剂的hpv纳米疫苗组合物及其制备方法
CN110680918B (zh) * 2019-10-10 2023-02-28 中国医学科学院医学生物学研究所 一种以atp为佐剂的hpv纳米疫苗组合物及其制备方法

Also Published As

Publication number Publication date
US20120128706A1 (en) 2012-05-24
US20090081247A1 (en) 2009-03-26
JPWO2009001673A1 (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
WO2007086001A3 (en) Novel pyridine derivatives
WO2008049116A3 (en) Substituted indoles
WO2007135527A3 (en) Benzimidazolyl compounds
MX2010004576A (es) Derivados de pirimidina novedosos.
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
WO2007146248A3 (en) Stable laquinimod preparations
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
WO2007087431A3 (en) Sublingual fentanyl spray
WO2009017837A3 (en) Sublingual fentanyl spray
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
WO2010070449A3 (en) Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2008006795A3 (en) Indole compounds
WO2007093365A3 (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2006094799A3 (en) Pyridinone derivatives against malaria
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2007064719A3 (en) Formulations of quinolinones

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765420

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009520440

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08765420

Country of ref document: EP

Kind code of ref document: A1